^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LXF821
i
Other names: CART-EGFRvIII T cells, LXF821
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis, University of Pennsylvania
Drug class:
EGFRvIII-targeted CAR-T immunotherapy
Related drugs:
